Abstract: The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so that high doses of the active vitamin D compound or the mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia. The invention also relates a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof in combination with one or more other therapeutic agents.

Abstract: The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so that high doses of the active vitamin D compound or the mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia. The invention also relates a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof in combination with one or more other therapeutic agents.

Abstract: Disclosed are methods of treating a male subject diagnosed with cognitive dysfunction that include administering an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof, to the male subject. Also disclosed is a method of improving cognitive function in a hypogonadal male subject that includes transdermally administering to the male subject a therapeutically effective amount of an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof. Further disclosed is a method of improving cognitive function in a male subject that includes administering to the male subject an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof, at a dosage of about 0.025 to about 1.5 mg/day.